Anika Therapeutics ANIK Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $41.02M-23.1% | $57.48M+3.3% | $57.99M-7.0% | $53.17M-15.4% | $53.37M-22.2% | ||
| $25.77M+17.2% | $23.69M+0.4% | $22.19M-21.8% | $23.96M-29.1% | $21.99M-31.5% | ||
| —— | —— | —— | —— | —— | ||
| $22.84M+7.0% | $18.79M-21.1% | $16.28M-58.9% | $16.92M-67.1% | $21.34M-56.8% | ||
| $3.94M-32.3% | $3.4M-38.1% | $5.13M-10.8% | $5.27M-24.0% | $5.82M-34.3% | ||
| $93.56M-8.7% | $103.36M-9.1% | $101.59M-25.4% | $99.32M-35.9% | $102.51M-35.5% | ||
| $39.72M-1.8% | $40.32M+3.4% | $40.68M-8.7% | $40.68M-14.7% | $40.46M-12.2% | ||
| $25.43M+1.0% | $25.94M+1.0% | $24.23M-11.0% | $24.72M-11.0% | $25.18M-10.6% | ||
| $7.89M+6.3% | $8.05M+13.0% | $8.05M+5.2% | $8.06M+9.6% | $7.42M+0.3% | ||
| $1.65M-27.7% | $1.65M-33.7% | $1.65M-46.4% | $1.66M-58.2% | $2.28M-46.9% | ||
| $1.15M-3.2% | $1.28M+8.3% | $1.25M-15.0% | $1.25M-7.9% | $1.19M-6.7% | ||
| $4.3M-24.8% | $4.03M-28.7% | $5.51M-51.3% | $5.55M-71.6% | $5.73M-67.4% | ||
| $179.39M-5.9% | $190.27M-6.2% | $189.44M-18.1% | $187.68M-28.5% | $190.61M-27.7% | ||
| $6.34M+20.1% | $6.04M+7.5% | $4.73M-30.5% | $4.77M-52.3% | $5.28M-47.3% | ||
| $14.63M+15.9% | $15.87M+17.0% | $14.36M-23.2% | $11.31M-29.9% | $12.62M-31.5% | ||
| $1.94M+3.6% | $2.05M+7.0% | $1.73M-24.7% | $1.82M— | $1.87M— | ||
| —— | —— | -$372K-138% | $888K— | $562K— | ||
| $20.97M+17.1% | $21.91M-6.0% | $19.09M-25.1% | $16.08M-38.4% | $17.9M-37.1% | ||
| $23.79M+1.0% | $24.2M+0.8% | $22.78M-9.7% | $23.17M-10.1% | $23.56M-10.6% | ||
| $726K-2.4% | $701K-9.2% | $761K-5.6% | $756K+85.7% | $744K+84.2% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $133K-7.0% | $139K-3.5% | $144K-2.0% | $144K-2.7% | $143K-3.4% | ||
| $83.35M-4.8% | $87.5M-1.6% | $91.11M-0.8% | $89.46M-4.0% | $87.56M-4.0% | ||
| $55.73M-16.6% | $60.79M-15.2% | $60.5M-35.3% | $62.82M-49.1% | $66.79M-45.9% | ||
| -$5.31M+13.0% | -$4.96M+26.9% | -$4.94M+13.4% | -$4.76M+25.9% | -$6.1M+3.4% | ||
| $133.9M-9.8% | $143.47M-6.8% | $146.81M-18.4% | $147.67M-29.8% | $148.4M-28.8% | ||
| $179.39M-5.9% | $190.27M-6.2% | $189.44M-18.1% | $187.68M-28.5% | $190.61M-27.7% | ||
| $25.77M+17.2% | $23.69M+0.4% | $22.19M-21.8% | $23.96M-29.1% | $21.99M-31.5% | ||
| $4.3M-24.8% | $4.03M-28.7% | $5.51M-51.3% | $5.55M-71.6% | $5.73M-67.4% | ||
| $25.43M+1.0% | $25.94M+1.0% | $24.23M-11.0% | $24.72M-11.0% | $25.18M-10.6% | ||
| $1.15M-3.2% | $1.28M+8.3% | $1.25M-15.0% | $1.25M-7.9% | $1.19M-6.7% | ||
| $1.65M-27.7% | $1.65M-33.7% | $1.65M-46.4% | $1.66M-58.2% | $2.28M-46.9% | ||
| $25.43M+1.0% | $25.94M+1.0% | $24.23M-11.0% | $24.72M-11.0% | $25.18M-10.6% | ||
| $4.3M-24.8% | $4.03M-28.7% | $5.51M-51.3% | $5.55M-71.6% | $5.73M-67.4% | ||
| $25.43M+1.0% | $25.94M+1.0% | $24.23M-11.0% | $24.72M-11.0% | $25.18M-10.6% | ||
| $4.3M-24.8% | $4.03M-28.7% | $5.51M-51.3% | $5.55M-71.6% | $5.73M-67.4% | ||
| $14.63M+15.9% | $15.87M+17.0% | $14.36M-23.2% | $11.31M-29.9% | $12.62M-31.5% | ||
| $25.74M+1.2% | $26.25M+1.2% | $24.51M-11.0% | $24.99M-11.0% | $25.44M-10.7% | ||
| $83.35M-4.8% | $87.5M-1.6% | $91.11M-0.8% | $89.46M-4.0% | $87.56M-4.0% | ||
| $133K-7.0% | $139K-3.5% | $144K-2.0% | $144K-2.7% | $143K-3.4% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $5.68M— | $5.64M— | $6.48M— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Anika Therapeutics's total assets?
- Anika Therapeutics (ANIK) holds $179.4M in total assets, down 5.9% year over year.
- How much debt does Anika Therapeutics have?
- Anika Therapeutics carries $25.7M in total debt against $133.9M of shareholders' equity, a debt-to-equity ratio of 0.19.
- How much cash does Anika Therapeutics have?
- Anika Therapeutics holds $41.0M in cash and equivalents.
- Can Anika Therapeutics cover its short-term obligations?
- Its current ratio is 4.46 — current assets exceed current liabilities.
- Where does Anika Therapeutics's balance sheet data come from?
- Every line is extracted from Anika Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
